Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Amplia Therapeutics Limited has reported a significant 149% increase in losses for the half-year ending September 2024, totaling $2.8 million, while revenues fell by 41% to approximately $1.5 million. Despite these challenges, the company remains focused on developing its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, with no dividends declared for the period.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- How Will Apple Be Affected by Google/DOJ Battle? Barclays Chimes In
- ‘Load Up Despite California’s EV Noise,’ Says Daniel Ives About Tesla Stock
- M&A News: Paramount (PARA) Turned Down Apollo Global Management Seven Times
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
